LC-002 is under clinical development by Genetic Immunity and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS). According to GlobalData, Phase II drugs for Human Immunodeficiency Virus (HIV) Infections (AIDS) have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LC-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LC-002 overview
LC-002 is under development for the prevention of HIV-1 infections. The vaccine candidate is applied transdermally as a patch. The vaccine candidate is a synthetic plasmid DNA-containing nanomedicine vaccine designed to resemble a naturally occurring pathogen. It is administered with the dendritic cell-targeting DermaPrep medical device. The nanomedicine consists of the core comprised of a condensed plasmid DNA with 15 HIV clade B protein antigens. The core is surrounded by a mannosylated polyethylenimine envelope. It is developed based on topical administration platform.
See Also:
Genetic Immunity overview
Genetic Immunity is a clinical stage biotechnology company that discovers, develops and commercializes immunotherapeutic biologics for the treatment of chronic viral infections, cancer and allergies. The company offers lead product candidate dermavir that is designed to boost immune response in order to kill HIV-infected cells in HIV-positive or AIDS patients whose immune system is compromised by the virus. It offers an immunetherapy platform technology that includes a plasmid DNA based antigen, a nanomedicine formulation, and a topical administration device that targets antigens to dendritic cells. The company conducts preclinical and clinical trial programs for HIV, cancer, allergies and viruses, among others. Genetic Immunity is headquartered in Budapest, Hungary.
For a complete picture of LC-002’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
